**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 66583

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Associations of new-onset atrial fibrillation and severe visual impairment in type 2 diabetes: A multicenter nationwide study**

Kaewput W *et al*. Atrial fibrillation and visual impairment among type 2 diabetes

Wisit Kaewput, Charat Thongprayoon, Ram Rangsin, Tarun Bathini, Michael A Mao, Wisit Cheungpasitporn

**Wisit Kaewput, Ram Rangsin,** Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand

**Charat Thongprayoon, Wisit Cheungpasitporn,** Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States

**Tarun Bathini,** Department of Internal Medicine, University of Arizona, Tucson, AZ 85721, United States

**Michael A Mao,** Department of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL 32224, United States

**Author contributions:** Kaewput W, Thongprayoon C and Cheungpasitporn W contributed to conceptualization; Kaewput W contributed to conceptualization data curation; Kaewput W, Thongprayoon C and Cheungpasitporn W contributed to formal analysis; Kaewput W and Thongprayoon C contributed to investigation; Kaewput W, Thongprayoon C and Cheungpasitporn W contributed to methodology; Rangsin R contributed to project administration; Rangsin R, Bathini T, Mao MA and Cheungpasitporn W contributed to supervision; Kaewput W and Thongprayoon C contributed to validation; Kaewput W, Thongprayoon C and Mao MA contributed to writing–original draft; Kaewput W, Thongprayoon C, Rangsin R, Bathini T, Mao MA and Cheungpasitporn W contributed to writing, review and editing.

**Corresponding author: Wisit Cheungpasitporn, FACP, FASN, FAST, Associate Professor,** Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States. wcheungpasitporn@gmail.com

**Received:** March 31, 2021

**Revised:** May 20, 2021

**Accepted:** July 19, 2021

**Published online:**

**Abstract**

BACKGROUND

Many studies have demonstrated an association between type 2 diabetes mellitus (T2DM) and atrial fibrillation (AF). However, the potential independent contributions of T2DM and AF to the prevalence of visual impairment have not been evaluated.

AIM

To determine whether such an association between T2DM and incident AF with visual impairment exists, and if so, the prevalence and magnitude of this association.

METHODS

We conducted a nationwide cross-sectional study based on the DM/HT study of the Medical Research Network of the Consortium of Thai Medical Schools. This study had evaluated adult T2DM patients from 831 public hospitals in Thailand in the year 2013. T2DM patients were categorized into two groups: patients without and with incident AF. T2DM patients without AF were selected as the reference group. The association between incident AF and visual impairment among T2DM patients was assessed using multivariate logistic regression.

RESULTS

A total of 27281 T2DM patients with available eye examination data were included in this analysis. The mean age was 60.7 ± 10.5 years, and 31.2% were male. The incident AF was 0.2%. The prevalence of severe visual impairment in all T2DM patients, T2DM patients without AF, and T2DM patients with incident AF were 1.4%, 1.4%, and 6.3%, respectively. T2DM patients with incident AF were associated with an increased OR of 3.89 (95%CI: 1.17-13.38) for severe visual impairment compared with T2DM patients without AF.

CONCLUSION

T2DM patients with incident AF were independently associated with increased severe visual impairment. Therefore, early eye screening should be provided for these high-risk individuals.

**Key Words:** Type 2 diabetes mellitus; Atrial fibrillation; Visual impairment; Retinopathy; Blindness

Kaewput W, Thongprayoon C, Rangsin R, Bathini T, Mao MA, Cheungpasitporn W. Associations of new-onset atrial fibrillation and severe visual impairment in type 2 diabetes: A multicenter nationwide study. *World J Cardiol* 2021; In press

**Core Tip:** The independent contributions of diabetes mellitus and atrial fibrillation (AF) to the prevalence of visual impairments have not been evaluated. AF is relatively common in diabetic patients and should be regarded as a marker of adverse outcomes for cardiovascular diseases in type 2 diabetes mellitus (T2DM). In this study, we explored whether an association between T2DM with incident AF and visual impairment exists, and if so, the prevalence and magnitude of this association. We found a nearly three-fold higher prevalence of severe visual impairment in T2DM patients with incident AF compared to those without AF [OR of 3.89 (95%CI: 1.17-13.38)]. It may be useful to increase screening for visual impairments in T2DM patients with incident AF. The results of our study could encourage public health initiatives for the prevention of vision impairment by early eye screening in these high-risk individuals.

**INTRODUCTION**

Type 2 diabetes mellitus (T2DM) is a common chronic disease worldwide[1]. T2DM is associated with significant morbidity and mortality and has rapidly emerged as a global public health issue[2,3]. Diabetic retinopathy and visual impairment are among these common and severe complications of T2DM.

Atrial fibrillation (AF) is the most common arrhythmia diagnosed in the world[4,5]. Its prevalence is predicted to more than double by 2050[6]. Previous studies found that AF may be relatively common in diabetic patients, and it should be regarded as a marker of increased adverse cardiovascular outcomes[7]. In addition, diabetes has long been recognized as a risk factor for AF[8,9]. The overlap of the pathophysiology of diabetes and AF concordantly increase the risk of thromboembolic events, and this has been well-established in the literature[10]. The potential independent contributions of diabetes and AF to the prevalence of visual impairment, however, has not been evaluated.

This study was thus aimed to determine whether such an association between T2DM and incident AF with visual impairment exists, and if so, the prevalence and magnitude of this association.

**MATERIALS AND METHODS**

***Study design and population***

This was an analysis of the DM/HT dataset from 2013[11]. This was a nationwide survey conducted annually in Thailand to evaluate the status of medical care in T2DM patients who visited the public hospitals of the Thai Ministry of Public Health and the clinics in the Thailand National Health Security Office’s program. The inclusion criteria of this DM/HT survey consisted of T2DM patients aged ≥ 35 years who received regular medical care in the targeted hospital for at least 12 mo. Patients who received care at primary care units outside Bangkok and university hospitals were excluded from this study. A two-stage stratified cluster sampling method was utilized to select a nationally and provincially representative sample of T2DM patients in Thailand. The first stage of sample collection consisted of the provinces that constituted 77 strata. The second stage of sample collection was the hospitals’ levels in each province, which were stratified into five strata according to the size of the hospital. These five strata were regional (> 500 beds), provincial (200-500 beds), large community (80-120 beds), medium community (60 beds), and small community (10-30 beds) hospitals. All regional (*n* = 25) and provincial (*n* = 70) hospitals were enrolled, but only 456 (62% out of 736) community hospitals were included. Of 456 community hospitals, 10%, 20%, and 70% were large, medium, and small community hospitals, respectively.

All patients were recruited from the outpatient clinic. Written informed consent was obtained from patients before enrolment. This study was approved by both the Institutional Review Board of the Royal Thai Army Medical Department and the Ethical Review Committee for Research in Human Subjects of the Ministry of Public Health of Thailand, due to the bureaucratic system regulations in Thailand. Well-trained research nurses reviewed medical records and collected data into a case record form. Data entry into this form was then transferred to the central data management of the Medical Research Network of the Consortium of Thai Medical Schools. This data management team adjudicated the process of data collection to ensure it was compiled according to the study protocol. This team was also responsible for inquiries to study sites to verify data. Site monitoring was randomly performed in approximately 10% of study sites. This study was conducted by the Strengthening the Reporting of Observational Studies in Epidemiology[12].

***Data collection***

Clinical characteristics, demographic information, medication, and laboratory data were collected using a manual data retrieval from the medical record as described above. The laboratory data included results from 12 mo prior to the consent process. Incident AF was identified by ICD10 code I48, and subsequently verified by medical record review during the 12 mo of the study period. This verification of AF consisted of electrocardiogram (ECG). The date of first ECG documenting the presence of AF was considered the onset of atrial fibrillation. We exclude patients who had prior history of AF before the start date. estimated glomerular filtration rate (eGFR) was estimated based on age, sex, race, and most recent creatinine with calculation *via* the Chronic Kidney Disease Epidemiology Collaboration equation[13]. CHA2DS2VASc score was calculated by using clinical data from the medical record. Primary outcome was diagnosis of severe visual impairment within 12 mo of data collection. Binocular visual acuity (VA) was examined using a semi-qualitative assessment and documented by physicians. Severe visual impairment was based on the worst VA exam of both eyes that consisted of “counting fingers,” “hand motions,” “projection of light,” “perception of light,” and “no light perception.”

***Statistical analysis***

Continuous variables were presented as mean ± SD. Categorical variables were presented as count with percentage. Clinical characteristics and outcomes were compared among the different groups using the independent t-test for continuous variables, and Chi-squared test, and Fisher’s exact test for categorical variables. T2DM patients were categorized into two groups: (1) T2DM patients without AF; and (2) T2DM patients with incident AF. T2DM patients without AF were selected as the reference group. Univariate and then multivariate logistic regression analysis, adjusting for priori-defined variables, were performed to assess the independent association between AF onset and severe visual impairment. Odds ratio (OR) with 95% confidence interval (CI) was reported. The adjusted variables consisted of age, sex, duration of T2DM, body mass index (BMI), smoking, comorbidities, complications, and medications. Comorbidities and complications were hypertension, ischemic heart disease, cerebrovascular disease, diabetic retinopathy, eGFR, and CHA2DS2VASc score. Medications were insulin, antiplatelets, and anticoagulants. A *P*-value < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 22 (SPSS, Inc., Chicago, IL, United States).

**RESULTS**

***Clinical characteristics***

A total of 27339 adult T2DM patients with eye examination data from 831 public hospitals in Thailand were included in this analysis. Clinical characteristics are summarized in Table 1. The mean age was 60.7 ± 10.5 years, and 31.2% were male. The mean diabetic duration was 7.1 ± 4.8 years. The mean BMI was 25.6 ± 4.5 kg/m2. The mean eGFR was 66.9 ± 25.9 mL/min per 1.73 m2. The mean CHA2DS2VASc was 2.9 ± 1.0. The prevalence of T2DM with incident AF was 0.2% (*n* = 48).

***Association between of AF and severe visual impairment in T2DM***

The prevalence of severe visual impairment in all T2DM was 1.4%. Severe visual impairment was documented in 1.4% of patients without AF and in 6.3% of patients with incident AF (Table 2).

In adjusted analysis, incident AF was associated with an increased OR of 3.89 (95%CI: 1.17-13.38) for severe visual impairment (Table 3).

**DISCUSSION**

An analysis of the baseline patient characteristics showed that T2DM with incident AF was associated with older age. Moreover, T2DM patients with AF had a higher prevalence of ischemic heart disease, cerebrovascular disease, and increased use of antiplatelet medications compared to patients without AF. These findings are consistent with a study performed by Nichols *et al*[14] and Benjamin *et al*[9], where AF was similarly found to be correlated with older age and ischemic heart disease. However, in their study, history of smoking was not associated with AF in T2DM patients. It is not surprisingly to find these associations, as it could be hypothesized that since these clinical characteristics are established risk factors for development of any cardiovascular diseases, it follows that they could also precipitate AF development in T2DM patients.

***Prevalence of severe visual impairment in T2DM patients***

The prevalence of severe visual impairment in all T2DM patients, T2DM patients without AF, and T2DM patients with incident AF were 1.4%, 1.4%, and 6.3%, respectively. According to previous studies from the United Kingdom[15] and the United States[3], the overall prevalence of visual impairment in T2DM ranges between 0.75% to 3.80%. Etiologies of visual impairment in T2DM patients include retinopathy of any type (particularly diabetic retinopathy), glaucoma, and cataracts[16]. A recent meta-analysis found that diabetes was associated with an increased incidence of glaucoma[3].

***Association between AF and severe visual impairment***

This study showed that AF is independently associated with severe visual impairment in adult T2DM patients. No prior studies have investigated this association. The pathogenesis of poor vision in recently diagnosed AF may be multifactorial, including retinal emboli[17,18]. Retinal artery occlusion (RAO)[19] and retinal vein occlusion (RVO)[20] are increasingly common in older subjects. As age increases, the risk of AF also substantially increases. Previous studies from Hayreh *et al*[21] and Yen *et al*[19] draw a potential pathophysiologic association, as they have reported that patients with AF are at increased risk of developing RAO. A study by Christiansen *et al*[22] also found that RAO was associated with an increased risk of incident AF. O'Mahoney *et al*[23] and Christiansen *et al*[24] reported that RVO might be an important cause of blindness in populations with high atherosclerotic risk. These conditions share the same traditional risk factors as for cardiovascular diseases, possibly due to shared pathophysiologic mechanisms.

Conditions like anterior ischemic optic neuropathy (AION)[25], age-related macular degeneration (AMD)[26,27], and cataracts may all be other potential etiologies for visual impairment in this population[28]. Callizo *et al*[25] found that AION may cause blindness in patients with AF. Clemons *et al*[26] and Topouzis *et al*[27] suggest an increased risk of AMD with diabetes mellitus. In a cohort study by Hahn *et al*[29], it was found that diabetic retinopathy might increase the risk of both dry and wet AMD. These studies support a potential similar pathophysiologic mechanism between diabetic retinopathy and AMD. Optimal diabetic control may reduce the development of AMD. Klein *et al*[28] found that T2DM is associated with an increased incidence and progression of cataracts, which may be worsened by suboptimal glycemic control. In summary, cardiovascular disease and its associated risk factors have an adverse effect on the incidence of age-related cataracts. These risk factors need to be promptly investigated in order to reduce ophthalmologic complications through early interventions.

***Strengths***

Our study consisted of a large-size sample from a multicenter and nationwide population-based design that provided detailed eye examination information while accounting for potential confounders in order to allow an adequate estimate of severe visual impairment burden in T2DM patients with AF. Our analysis of the association between eGFR and DR utilized a multiple logistic regression model that accounted for several possible confounders, including age, sex, duration of T2DM, body mass index (BMI), smoking, other comorbidities, and medications. Comorbidities included hypertension, ischemic heart disease, cerebrovascular disease, and diabetic retinopathy. Medications that were adjusted for included insulin and antiplatelet medication. Lastly, visual impairment severity was measured using a semi- qualitative clinical scale composed of bedside testing items, which is an easy test to perform in the community setting.

***Limitations***

This study had several limitations. First, we identified AF using ICD 10 codes and then subsequently confirmed by medical record review for documented ECGs. As ECGs were usually performed when clinically indicated rather than universally, our study may have underdiagnosed asymptomatic AF. This may explain the low prevalence of AF in our study compared to previous reports[30-33]. Future studies utilizing advanced cardiac monitoring technology such as signal-averaged ECGs and Holter monitors would more accurately capture total prevalence of AF. In addition, AF could be paroxysmal, and periodic ECGs may not have detected these paroxysmal AF episodes. Thus, future studies are needed to better assess the associations of visual impairment with asymptomatic AF and AF subtypes among T2DM patients. Second, our study was cross-sectional in nature. A longitudinal study in the future may provide further details on the etiology of visual impairments in order to better confirm the association and elucidate the pathophysiology of new-onset AF and poor vision in T2DM patients. Third, information on prior eye surgeries, such as vitrectomy due to retinal hemorrhage, was scarce. These patients may have suffered a prior visual impairment rather than incorrectly associated with incident AF. Fourth, information on the etiology of visual impairment other than diabetic retinopathy was not available. Finally, although we performed multivariate analysis for further adjustment of potential confounders including CHA2DS2-VASC and anticoagulation, we did not have information on the specific type of AF, type of anticoagulation therapy used, international normalized ratio (INR) levels, previous AF medications for rate control, and outcomes of AF treatment. These are potential confounding factors that were unaccounted for. Therefore, this study was unable to determine the association between optimally treated AF and visual impairment in T2DM patients.

***Implications***

Our study found a nearly three-fold higher prevalence of poor vision in T2DM patients with incident AF. Several conditions such as glaucoma, cataracts, and retinopathy are potentially reversible causes of vision impairment, especially if treated early. It may be useful to screen for visual impairment and its etiologies in T2DM patients with recent-onset AF (less than 1-year). The results of our study could encourage public health initiatives to institute early eye screening in these high-risk individuals in order to prevent vision impairment. Further studies are needed to elucidate whether these interventions would translate into improved clinical outcomes.

**CONCLUSION**

The prevalence of severe visual impairment in T2DM patients with incident AF was nearly three times higher than the prevalence of impaired vision in all T2DM patients. Moreover, T2DM patients with incident AF were independently associated with severe visual impairment. Early eye screening should be performed in these high-risk individuals as it may provide an earlier diagnosis, allowing for prevention and treatment of potentially reversible causes of vision impairment.

**ARTICLE HIGHLIGHTS**

***Research background***

Previous studies have shown an association between type 2 diabetes mellitus (T2DM) and atrial fibrillation (AF). However, the independent contributions of T2DM and AF on the prevalence of visual impairment have not been evaluated.

***Research motivation***

Earlier studies have demonstrated that AF is relatively common in diabetic patients, and it should be regarded as a marker for adverse cardiovascular outcomes in T2DM.

***Research objectives***

To investigate whether an association between T2DM and incident AF with visual impairment exists, and if so, the prevalence and magnitude of this association.

***Research methods***

This study evaluated adult T2DM patients from 831 public hospitals in Thailand in the year 2013. The association between T2DM with incident AF and visual impairment were assessed using multivariate logistic regression.

***Research results***

A total of 27281 T2DM patients with available eye examination data were included in this analysis. The prevalence of incident AF in T2DM patients was 0.2%. The prevalence of severe visual impairment in all T2DM patients, T2DM patients without AF, and T2DM patients with incident AF were 1.4%, 1.4%, and 6.3%, respectively. T2DM patients with incident AF were associated with an increased OR of 3.89 (95%CI: 1.17-13.38) for severe visual impairment compared to those without AF.

***Research conclusions***

T2DM patients with incident AF were independently associated with severe visual impairment. Early eye screening should be provided for these high-risk individuals.

***Research perspectives***

Overlapping diabetes and AF leads to an increased risk of thromboembolic events. However, the independent contribution of T2DM and AF to the prevalence of visual impairments has not been evaluated. Therefore, it may be useful to screen for visual impairment and its etiologies in T2DM patients with incident AF.

**ACKNOWLEDGEMENTS**

The authors wish to thank the Medical Research Network of the Consortium of Thai Medical Schools (MedResNet) Thailand, which granted access to the diabetes and hypertension dataset in the DAMUS website (http://www.damus.in.th/damus/index.php).

**REFERENCES**

1 **Ogurtsova K**, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res Clin Pract* 2017; **128**: 40-50 [PMID: 28437734 DOI: 10.1016/j.diabres.2017.03.024]

2 **Teo ZL**, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, Wong IY, Ting DSW, Tan GSW, Jonas JB, Sabanayagam C, Wong TY, Cheng CY. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. *Ophthalmology* 2021 [PMID: 33940045 DOI: 10.1016/j.ophtha.2021.04.027]

3 **Das T**, Takkar B, Sivaprasad S, Thanksphon T, Taylor H, Wiedemann P, Nemeth J, Nayar PD, Rani PK, Khandekar R. Recently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilities. *Eye (Lond)* 2021 [PMID: 33976399 DOI: 10.1038/s41433-021-01572-4]

4 **Zhang J**, Johnsen SP, Guo Y, Lip GYH. Epidemiology of Atrial Fibrillation: Geographic/Ecological Risk Factors, Age, Sex, Genetics. *Card Electrophysiol Clin* 2021; **13**: 1-23 [PMID: 33516388 DOI: 10.1016/j.ccep.2020.10.010]

5 **Kaneko H**, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Carey RM, Lima JAC, Oparil S, Yasunaga H, Komuro I. Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. *Circulation* 2021; **143**: 2244-2253 [PMID: 33886370 DOI: 10.1161/CIRCULATIONAHA.120.052624]

6 **Go AS**, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001; **285**: 2370-2375 [PMID: 11343485]

7 **Du X**, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, Lip GY, Patel A; ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. *Eur Heart J* 2009; **30**: 1128-1135 [PMID: 19282274 DOI: 10.1093/eurheartj/ehp055]

8 **Higa S**, Maesato A, Ishigaki S, Suenari K, Chen YJ, Chen SA. Diabetes and Endocrine Disorders (Hyperthyroidism/Hypothyroidism) as Risk Factors for Atrial Fibrillation. *Card Electrophysiol Clin* 2021; **13**: 63-75 [PMID: 33516408 DOI: 10.1016/j.ccep.2020.11.005]

9 **Benjamin EJ**, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *JAMA* 1994; **271**: 840-844 [PMID: 8114238]

10 **Tsang TS**, Petty GW, Barnes ME, O'Fallon WM, Bailey KR, Wiebers DO, Sicks JD, Christianson TJ, Seward JB, Gersh BJ. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. *J Am Coll Cardiol* 2003; **42**: 93-100 [PMID: 12849666]

11 **Medical Research Network of the Consortium of Thai Medical Schools: MedResNet (Thailand).** Data Archival for Maximum Utilization System (DAMUS). DM/HT study (NHSO Research Project) 2013. [cited 2 February 2018]. Available from: http://www.damus.in.th/damus/index.php

12 **von Elm E**, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg* 2014; **12**: 1495-1499 [PMID: 25046131 DOI: 10.1016/j.ijsu.2014.07.013]

13 **Levey AS**, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**: 604-612 [PMID: 19414839]

14 **Nichols GA**, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. *Diabetes Care* 2009; **32**: 1851-1856 [PMID: 19794003 DOI: 10.2337/dc09-0939]

15 **Prasad S**, Kamath GG, Jones K, Clearkin LG, Phillips RP. Prevalence of blindness and visual impairment in a population of people with diabetes. *Eye (Lond)* 2001; **15**: 640-643 [PMID: 11702977 DOI: 10.1038/eye.2001.200]

16 **Sayin N**, Kara N, Pekel G. Ocular complications of diabetes mellitus. *World J Diabetes* 2015; **6**: 92-108 [PMID: 25685281 DOI: 10.4239/wjd.v6.i1.92]

17 **Klein R**, Klein BE, Moss SE, Meuer SM. Retinal emboli and cardiovascular disease: the Beaver Dam Eye Study. *Arch Ophthalmol* 2003; **121**: 1446-1451 [PMID: 14557181 DOI: 10.1001/archopht.121.10.1446]

18 **Plunkett O**, Lip PL, Lip GY. Atrial fibrillation and retinal vein or artery occlusion: looking beyond the eye. *Br J Ophthalmol* 2014; **98**: 1141-1143 [PMID: 24642665 DOI: 10.1136/bjophthalmol-2013-304646]

19 **Yen JC**, Lin HL, Hsu CA, Li YC, Hsu MH. Atrial Fibrillation and Coronary Artery Disease as Risk Factors of Retinal Artery Occlusion: A Nationwide Population-Based Study. *Biomed Res Int* 2015; **2015**: 374616 [PMID: 26558268 DOI: 10.1155/2015/374616]

20 **Wong TY**, Larsen EK, Klein R, Mitchell P, Couper DJ, Klein BE, Hubbard LD, Siscovick DS, Sharrett AR. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. *Ophthalmology* 2005; **112**: 540-547 [PMID: 15808241 DOI: 10.1016/j.ophtha.2004.10.039]

21 **Hayreh SS**, Podhajsky PA, Zimmerman MB. Retinal artery occlusion: associated systemic and ophthalmic abnormalities. *Ophthalmology* 2009; **116**: 1928-1936 [PMID: 19577305 DOI: 10.1016/j.ophtha.2009.03.006]

22 **Christiansen CB**, Torp-Pedersen C, Olesen JB, Gislason G, Lamberts M, Carlson N, Buron M, Juul N, Lip GYH. Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study. *BMC Cardiovasc Disord* 2018; **18**: 91 [PMID: 29743025 DOI: 10.1186/s12872-018-0825-1]

23 **O'Mahoney PR**, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. *Arch Ophthalmol* 2008; **126**: 692-699 [PMID: 18474782 DOI: 10.1001/archopht.126.5.692]

24 **Christiansen CB**, Lip GY, Lamberts M, Gislason G, Torp-Pedersen C, Olesen JB. Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation. *J Thromb Haemost* 2013; **11**: 1485-1492 [PMID: 23663383 DOI: 10.1111/jth.12297]

25 **Callizo J**, Feltgen N, Ammermann A, Ganser J, Bemme S, Bertelmann T, Pfeiffer S, Duvinage A, Gröschel K, Hoerauf H, Wachter R. Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy. *PLoS One* 2017; **12**: e0181766 [PMID: 28771491 DOI: 10.1371/journal.pone.0181766]

26 **Clemons TE**, Milton RC, Klein R, Seddon JM, Ferris FL 3rd; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. *Ophthalmology* 2005; **112**: 533-539 [PMID: 15808240 DOI: 10.1016/j.ophtha.2004.10.047]

27 **Topouzis F**, Anastasopoulos E, Augood C, Bentham GC, Chakravarthy U, de Jong PT, Rahu M, Seland J, Soubrane G, Tomazzoli L, Vingerling JR, Vioque J, Young IS, Fletcher AE. Association of diabetes with age-related macular degeneration in the EUREYE study. *Br J Ophthalmol* 2009; **93**: 1037-1041 [PMID: 19429584 DOI: 10.1136/bjo.2008.146316]

28 **Klein BE**, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. *Am J Ophthalmol* 1998; **126**: 782-790 [PMID: 9860001]

29 **Hahn P**, Acquah K, Cousins SW, Lee PP, Sloan FA. Ten-year incidence of age-related macular degeneration according to diabetic retinopathy classification among medicare beneficiaries. *Retina* 2013; **33**: 911-919 [PMID: 23407352 DOI: 10.1097/IAE.0b013e3182831248]

30 **Zhao YX**, Chen XW. Diabetes and risk of glaucoma: systematic review and a Meta-analysis of prospective cohort studies. *Int J Ophthalmol* 2017; **10**: 1430-1435 [PMID: 28944204 DOI: 10.18240/ijo.2017.09.16]

31 **January CT**, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2019; **74**: 104-132 [PMID: 30703431 DOI: 10.1016/j.jacc.2019.01.011]

32 **Ponamgi SP**, Siontis KC, Rushlow DR, Graff-Radford J, Montori V, Noseworthy PA. Screening and management of atrial fibrillation in primary care. *BMJ* 2021; **373**: n379 [PMID: 33846159 DOI: 10.1136/bmj.n379]

33 **Nguyen TN**, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. *Int J Cardiol* 2013; **167**: 2412-2420 [PMID: 23453870 DOI: 10.1016/j.ijcard.2013.01.184]

**Footnotes**

**Institutional review board statement:** This study was approved by both the Institutional Review Board of the Royal Thai Army Medical Department and the Ethical Review Committee for Research in Human Subjects, the Ministry of Public Health of Thailand (IRB# S007h/54).

**Informed consent statement:** All patients were recruited from the outpatient clinic. Written informed consent was obtained from patients before enrolment.

**Conflict-of-interest statement:** The authors deny any conflict of interest.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** April 1, 2021

**First decision:** May 11, 2021

**Article in press:**

**Specialty type:** Medicine, general and internal

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Abdul Jalal MJ, Balduzzi A, Rajput MA **S-Editor:** Ma YJ **L-Editor: P-Editor:**

**Table 1 Baseline characteristics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics** | **All** | **T2DM without AF** | **Incident AF** | ***P* value** |
| *N*/*n* (%) | 27339 | 27281 (99.8) | 48 (0.2) |   |
| Age (yr, mean ± SD) | 60.7 ± 10.5 | 60.7 ± 10.5 | 65.9 ± 9.9 | 0.001 |
| Male, *n* (%) | 8518 (31.2) | 8499 (31.1) | 19 (39.6) | 0.21 |
| Duration of T2DM (yr, mean ± SD) | 7.1 ± 4.8 | 7.1 ± 4.8 | 6.6 ± 3.4 | 0.46 |
| Body mass index (kg/m2, mean ± SD) | 25.6 ± 4.5 | 25.6 ± 4.5 | 24.8 ± 4.5 | 0.24 |
| Smoking, *n* (%) | 1084 (4.0) | 1080 (4.0) | 4 (8.5) | 0.12 |
| Comorbidity and complication, *n* (%) |   |   |   |   |
| Hypertension | 19840 (72.6) | 19801 (72.6) | 39 (81.3) | 0.18 |
| Ischemic heart disease | 947 (3.5) | 939 (3.4) | 8 (16.7) | < 0.001 |
| Cerebrovascular disease | 666 (2.4) | 661 (2.4) | 5 (10.4) | 0.01 |
| Diabetic retinopathy | 2008 (7.4) | 2005 (7.4) | 3 (6.7) | 1.00 |
| Medication, *n* (%) |  |  |  |  |
| Insulin use | 5848 (21.4) | 5840 (21.4) | 8 (16.7) | 0.42 |
| Antiplatelets or anticoagulants | 16321 (60.1) | 16285 (60.1) | 36 (75.0) | 0.04 |
| eGFR (ml/min/1.73 m2, mean ± SD) | 66.9 ± 25.9 | 66.9 ± 25.9 | 60.5 ± 25.7 | 0.09 |
| CHA2DS2VASc score (mean ± SD) | 2.9 ± 1.0 | 2.9 ± 1.0 | 3.7 ± 1.4 | 0.001 |

AF: Atrial fibrillation; T2DM: Type 2 diabetes mellitus; eGFR: Estimated glomerular filtration rate.

**Table 2 Prevalence of severe visual impairments stratified by presence of incident atrial fibrillation in type 2 diabetes mellitus patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcomes** | **All** | **T2DM without AF** | **Incident AF** | ***P* value** |
| Severe visual impairment, *n* (%) | 387 (1.4) | 384 (1.4) | 3 (6.3) | 0.03 |
| Counting finger, *n* (%) | 181 (0.7) | 181 (0.7) | 0 (0) | 1.00 |
| Hand movement, *n* (%) | 101 (0.4) | 99 (0.4) | 2 (4.2) | 0.01 |
| Projection of light, *n* (%) | 18 (0.1) | 18 (0.1) | 0 (0) | 1.00 |
| Perception of light, *n* (%) | 24 (0.1) | 24 (0.1) | 0 (0) | 1.00 |
| No light perception, *n* (%) | 77 (0.3) | 76 (0.3) | 1 (2.1) | 0.13 |

T2DM: type 2 diabetes mellitus; AF: atrial fibrillation.

**Table 3 Association of incident atrial fibrillation and severe visual impairment in type 2 diabetes mellitus patients after multivariate logistic regression analysis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Crude OR (95%CI)** | ***P* value** | **Adjusted OR (95%CI)1,2** | ***P* value** |
| T2DM without AF | 1 (Reference) | 1 (Reference)  |
| Incident AF | 4.67 (1.45-15.10) | 0.01 | 3.89 (1.17-13.38) | 0.03 |

1Adjusted for age (continuous), gender (male or female), duration of T2DM (continuous), body mass index (continuous), smoking (yes or no), hypertension (yes or no), ischemic heart disease (yes or no), cerebrovascular disease (yes or no), diabetic retinopathy (yes or no), insulin (yes or no), antiplatelets or anticoagulants (yes or no), eGFR (continuous), and CHA2DS2Vasc score (continuous). 2Hosmer-Lemeshow test: Chi-square 13.31, *P*-value 0.10. AF: atrial fibrillation; T2DM: type 2 diabetes mellitus; eGFR: estimated glomerular filtration rate.